Open AccessReal-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer
Author(s) -
Shuai Liu,
Lu Lu,
Feng Pan,
Chunsheng Yang,
Jing Liang,
Jinfeng Liu,
Jian Wang,
Rong Shen,
Fu-Ze Xin,
Nan Zhang
Publication year - 2022
Publication title -
oncology research
Language(s) - English
Resource type - Journals
eISSN - 1555-3906
pISSN - 0965-0407
DOI - 10.3727/096504022x16427607626672
Subject(s) - medicine , adverse effect , colorectal cancer , stomatitis , clinical trial , toxicity , oncology , surgery , cancer
Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co., Ltd, Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal cancer (mCRC) patients. The purpose of this study is to retrospectively evaluate the efficacy and toxicity of fruquintinib in real-world patients. We collected data from patients with mCRC treated with oral fruquintinib from 2018 to 2020 in 6 different institutions. Patients with mCRC initially received 5mg of oral fruquintinib daily for 3 weeks. Progression-free survival(PFS)was evaluated using the Kaplan-Meier method. The efficacy and safety of fruquintinib were also assessed. Seventy-five patients were involved in our study, and 29.3% of patients achieved stable disease (SD). Median PFS was 5.4 months (95% CI 4.841–5.959). The treatment emergent adverse events (TEAEs) with fruquintinib were acceptable with the grade 3 TEAEs of 6%. The grade 3 TEAEs were hand-foot skin reaction (HFSR), fatigue, and stomatitis. The ECOG performance status was associated with PFS. In this real-world study, the clinical activity of fruquintinib was consistent with what has been reported in previous clinical trials. The level of safety was acceptable, and the side effects were manageable.